Codagenix has filed a notice of an exempt offering of securities to raise $25,000,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Codagenix is raising $25,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, John Coleman played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Codagenix
Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development. Codagenix uses a computer-based algorithm, called SAVE (Synthetic Attenuated Virus Engineering) to design viral genomes that are identical to the wild type strain at the amino acid level, but make less protein in human cells. The highly attenuated viruses make excellent vaccines or oncolytics against solid tumors. Codagenix represents the next wave in vaccine technology, untethered from traditional, time-consuming and unpredictable approaches to attenuating viruses.
To learn more about Codagenix, visit http://codagenix.com/
Contact:
John Coleman, Chief Executive Officer
631-227-3932
SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.